Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature
- PMID: 16418211
- DOI: 10.1210/jc.2005-2153
Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature
Abstract
Context: Polycystic ovary syndrome (PCOS) is defined most commonly according to the proceedings of an expert conference sponsored by the National Institutes of Health (NIH) in April 1990, which noted the disorder as having 1) hyperandrogenism and/or hyperandrogenemia, 2) oligoovulation, and 3) exclusion of known disorders. Alternatively, another expert conference held in Rotterdam in May 2003 defined PCOS, after the exclusion of related disorders, by two of the following three features: 1) oligo- or anovulation, 2) clinical and/or biochemical signs of hyperandrogenism, or 3) polycystic ovaries. In essence, the Rotterdam 2003 expanded the NIH 1990 definition creating two new phenotypes: 1) ovulatory women with polycystic ovaries and hyperandrogenism, and 2) oligoanovulatory women with polycystic ovaries, but without hyperandrogenism.
Objective: The objective of this study was to ascertain the validity of using the Rotterdam 2003 criteria rather than the NIH 1991 criteria for the diagnosis of PCOS.
Intervention(s): Interventions included the use of the Rotterdam 2003 criteria for diagnosing PCOS and, in particular, the proposal to define two new phenotypes as PCOS. POSITIONS: Available data suggest that hyperandrogenic ovulatory women with polycystic ovaries tend to have mild insulin resistance and mild evidence of ovarian dysfunction, although significantly less than women with anovulatory PCOS. However, whether these women will have an increased risk of infertility or metabolic complications, such as type 2 diabetes, remains to be determined. Alternatively, the risk of insulin resistance and long-term metabolic risks of oligoovulatory women with polycystic ovaries is even less well characterized and may be nonexistent.
Conclusions: Because of the paucity of data on the two new phenotypes and their long-term implications and the potential negative impact on research, clinical practice, and patient insurability, the adoption of the Rotterdam 2003 criteria for defining PCOS should be considered premature. However, because polycystic ovaries are a frequent feature of PCOS, a modification of the NIH 1990 criteria is proposed. Additional research characterizing the phenotypes and associated morbidities of PCOS is urgently required.
Similar articles
-
Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria.J Clin Endocrinol Metab. 2006 Mar;91(3):786-9. doi: 10.1210/jc.2005-2501. Epub 2006 Jan 17. J Clin Endocrinol Metab. 2006. PMID: 16418209 Review.
-
PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors.BJOG. 2006 Oct;113(10):1210-7. doi: 10.1111/j.1471-0528.2006.01008.x. BJOG. 2006. PMID: 16972863
-
Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.Arch Gynecol Obstet. 2006 Jul;274(4):227-32. doi: 10.1007/s00404-006-0173-8. Epub 2006 May 12. Arch Gynecol Obstet. 2006. PMID: 16691383
-
The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone.Hum Reprod. 2014 Apr;29(4):791-801. doi: 10.1093/humrep/det469. Epub 2014 Jan 16. Hum Reprod. 2014. PMID: 24435776
-
PCOS: a diagnostic challenge.Reprod Biomed Online. 2004 Jun;8(6):644-8. doi: 10.1016/s1472-6483(10)61644-6. Reprod Biomed Online. 2004. PMID: 15169578 Review.
Cited by
-
Obesity and PCOS: implications for diagnosis and treatment.Semin Reprod Med. 2012 Dec;30(6):496-506. doi: 10.1055/s-0032-1328878. Epub 2012 Oct 16. Semin Reprod Med. 2012. PMID: 23074008 Free PMC article. Review.
-
Effect of metformin on serum ferritin level in women with polycystic ovary syndrome.Iran Red Crescent Med J. 2011 Jul;13(7):487-92. Epub 2011 Jul 1. Iran Red Crescent Med J. 2011. PMID: 22737516 Free PMC article.
-
Sequential 2.5 mg letrozole/FSH therapy is more effective for promoting pregnancy in infertile women with PCOS: a pragmatic randomized controlled trial.Front Endocrinol (Lausanne). 2024 Jan 15;14:1294339. doi: 10.3389/fendo.2023.1294339. eCollection 2023. Front Endocrinol (Lausanne). 2024. PMID: 38283747 Free PMC article. Clinical Trial.
-
Function of MicroRNAs in Normal and Abnormal Ovarian Activities: A Review Focus on MicroRNA-21.Int J Fertil Steril. 2024 Feb 2;18(2):94-99. doi: 10.22074/ijfs.2023.1985792.1415. Int J Fertil Steril. 2024. PMID: 38368510 Free PMC article.
-
Polycystic ovary syndrome is associated with an increased prevalence of irritable bowel syndrome.Dig Dis Sci. 2010 Apr;55(4):1085-9. doi: 10.1007/s10620-009-0890-5. Epub 2009 Aug 21. Dig Dis Sci. 2010. PMID: 19697132
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous